Traws Pharma, Inc. is a clinical stage biopharmaceutical company dedicated to developing novel therapies to target critical threats to human health in respiratory viral diseases. It integrates antiviral drug development, medical intelligence and regulatory strategy in the treatment of viral diseases. The Cadvancing novel investigational oral small-molecule antiviral agents that have potent activity against difficult to treat or resistant virus strains that threaten human health: bird flu and seasonal influenza, and COVID-19/Long COVID. Its four clinical programs consist of Tivoxavir marboxil, Ratutrelvir (TRX0), Narazaciclib, and Rigosertib. Tivoxavir marboxil is a small-molecule cap-dependent endonuclease inhibitor. Ratutrelvir (TRX01) is an inhibitor of the main protease (also known as 3CL protease) of the SARS-CoV-2 virus. arazaciclib is its oral CDK4-plus inhibitor intended initially to treat breast cancers, endometrial and other cancers. Rigosertib is its second asset in oncology.

Employees

Sector

Biotechnology & Medical Research

More about the company

Market Cap	13.51M 11.87M 10.94M 10.24M 19.18M 1.28B 19.51M 131M 50.84M 628M 50.72M 49.63M 2.18B	P/E 2026 *	-0.63x	P/E 2027 *	-0.7x
Enterprise Value	13.51M 11.87M 10.94M 10.24M 19.18M 1.28B 19.51M 131M 50.84M 628M 50.72M 49.63M 2.18B	EV / Sales 2026 *	-	EV / Sales 2027 *	-
Free-Float	90.56%	Yield 2026 *	-	Yield 2027 *	-

06-22	Traws Pharma Provides Updated Guidance on Influenza Prophylaxis Program	CI
06-22	Traws Pharma Says Updated Toxicology Data Being Developed on Influenza Prophylaxis Program	MT
06-15	Top Premarket Decliners	MT
06-15	Ladenburg Thalmann Downgrades Traws Pharma to Neutral From Buy, Price Target is $3	MT
06-15	Traws Pharma Delays Phase 2 Influenza Study After UK Regulatory Review; Shares Down Pre-Bell	MT
06-12	Traws Pharma Provides Regulatory Update on Influenza Program	CI
05-27	Traws Pharma Advances Novel Broad-Spectrum Combination Antiviral Agent Targeting Hantavirus And Ebola Virus Disease Outbreaks	CI
05-22	Traws Pharma Inc files for offering of up to $3.1 million in common stock	RE
05-20	Hantavirus vaccines and treatments under development	RE
05-15	Traws Pharma, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
05-08	Traws Pharma Expands Antiviral Program to Target Hantavirus Infections; Shares Up Pre-Bell	MT
05-08	Traws Pharma to advance potential clinical candidates for the treatment of Hantavirus infections	RE
05-08	Traws Pharma, Inc. Advances Potential Clinical Candidates For The Treatment Of Hantavirus Infections	CI

06-15	Ladenburg Thalmann Downgrades Traws Pharma to Neutral From Buy, Price Target is $3	MT
12-03	HC Wainwright Initiates Traws Pharma at Buy With $8 Price Target	MT
23-04-21	HC Wainwright Upgrades Onconova Therapeutics to Buy From Neutral, Price Target is $11	MT
22-03-01	Ladenburg Thalmann Starts Onconova Therapeutics at Buy With $7 Price Target	MT
21-05-18	ONCONOVA THERAPEUTICS : Guggenheim Starts Onconova Therapeutics at Buy With $4 Price Target	MT

06-22	Traws Pharma Provides Updated Guidance on Influenza Prophylaxis Program	AQ
06-12	Traws Pharma Provides Regulatory Update on Influenza Program	AQ
05-27	Traws Pharma Announces Antiviral Program Targeting Ongoing Hantavirus and Ebola Virus Disease Outbreaks	AQ
05-15	Traws Pharma Provides Business Highlights and Reports Q1 2026 Financial Results	AQ
05-11	Traws Pharma to Advance Potential Clinical Candidates for the Treatment of Hantavirus Infections	AQ

04-14	HVIVO flambe grâce à un contrat
21-03-17	Aktien New York Schluss: Dow auf Rekordhoch - Geldpolitik bleibt locker
21-03-17	Aktien New York: Überwiegend Verluste kurz vor geldpolitischen Signalen der Fed
21-03-17	Aktien New York Ausblick: Zurückhaltung vor geldpolitischen Signale der Fed

Onconova Therapeutics Inc Stock Nasdaq

Stocks

US68232V3069

Biotechnology & Medical Research

Valuation: Onconova Therapeutics Inc

Latest news : Onconova Therapeutics Inc

Last Transcript: Onconova Therapeutics Inc

Analysts' recommendations: Onconova Therapeutics Inc

Press Releases: Onconova Therapeutics Inc

News in other languages: Onconova Therapeutics Inc

Quotes and Performance

Managers and Directors: Onconova Therapeutics Inc

Other Biotechnology & Medical Research

Financials

Company Profile

Manager	Title	Age	Since
Iain Dukes CEO	Chief Executive Officer	67	2025-03-30
Charles Parker DFI	Director of Finance/CFO	46	2025-07-04
Robert Redfield CTO	Chief Tech/Sci/R&D Officer	74	2024-03-31

Director	Title	Age	Since
Jack Stover CHM	Chairman	73	2025-04-14
Mary Shoemaker BRD	Director/Board Member	64	2020-03-31
Trafford Clarke BRD	Director/Board Member	67	2022-12-18

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
ONCONOVA THERAPEUTICS INC	-11.77%	-7.89%	-	-	13.51M
LONZA GROUP AG	+2.96%	+4.21%	-8.16%	-2.76%	43.24B
REVOLUTION MEDICINES, INC.	+1.73%	+7.92%	+322.03%	+562.15%	35.25B
BEONE MEDICINES AG	+1.32%	+4.30%	+6.89%	+53.54%	30.22B
IQVIA HOLDINGS INC.	+2.27%	-4.01%	+10.84%	-19.66%	28.01B
CELLTRION, INC.	-4.75%	-8.29%	+3.90%	+13.88%	24.08B
ASCENDIS PHARMA A/S	+2.89%	+1.23%	-	-	14.16B
MEDPACE HOLDINGS, INC.	+2.59%	+0.99%	+51.04%	+108.68%	13.01B
EUROFINS SCIENTIFIC SE	+2.77%	+4.02%	+9.61%	+15.31%	12.7B
IONIS PHARMACEUTICALS, INC.	+1.09%	+5.32%	+104.35%	+94.20%	12.54B
Average	+0.08%	-0.78%	+62.56%	+103.17%	23.69B
Weighted average by Cap.	+1.34%	-0.72%	+68.83%	+120.02%

	2026 *	2027 *
Net sales	-	-
Net income	-21.3M -18.71M -17.24M -16.14M -30.24M -2.02B -30.75M -207M -80.14M -990M -79.96M -78.24M -3.44B	-24.25M -21.3M -19.63M -18.38M -34.43M -2.3B -35.01M -236M -91.24M -1.13B -91.03M -89.08M -3.92B
Net Debt	-	-